Best Life Sciences Companies in Wuhan, China
The 35 best Life Sciences companies in Wuhan, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Binhui Bio.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Wuhan
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | bms Medicaltech Developer of blood collection and separation equipment | — | — | Unfunded | Lisa He CEO | 65 | — | 8 patents Sterile blood bag connectors, liquid extraction devices, and intelligent blood sampling systems. | — |
| 2 | CABIO Biotech Provider of nutritional ingredients and innovative solutions for human, animal, and personal care applications | — | — | Funding Raised | — | 444 | — | — | — |
| 3 | Cusabio Manufacturer of raw materials for IVD, reagents for for research services | — | — | Unfunded | — | 34 | Priority HintsOWL CarouseljQuery+7 | — | 2 launchs |
| 4 | Dimed Laser Portfolio of medical laser devices | — | — | Unfunded | Karen Rene CEO & Director | — | WordPressMySQLRedis+24 | — | — |
| 5 | Dragonbio Developer of surgical implants | — | — | Unfunded | Zhou Yongjun Founder | — | — | — | — |
| 6 | EIAab Develops and markets lifescience instruments and reagents | — | — | Unfunded | Kai Wang CEO | — | — | — | — |
| 7 | Elabscience Manufacturer of reagents of immunodiagnostic technology | — | — | Unfunded | Yibin Leng CEO | — | Cart FunctionalityAnimate.cssUnoCSS+22 | — | — |
| 8 | EnkiLife Provider of reagents, antibodies, kits, and dyes for life science research | — | — | Unfunded | Leo Wang Founder & CEO | — | — | — | — |
Top 12 Life Sciences companies in Wuhan
#1
Series B · Wuhan, Hubei · founded 2017$40Mraised▾
Developer of cell therapies to treat neurological and ophthalmological diseases. The company focuses on the development of a new generation of chemically induced cell therapy products, for untreatable diseases, such as Parkinson's disease and blindness. The company's product pipeline includes NN001 and NN002 for neurological disorders, NS001, and NS001 for diabetic neuropathy and optic neuropathy.
- Sep 2025Series B$40M
- Aug 2021Series A—
- Jul 2020Seed—
- Jan 2019Seed—
#2
Series C · Wuhan, Hubei · founded 2016 · 76 employees$125Mraised▾
Developer of drugs for retina-related diseases. By using the AAV gene therapy platform the company has developed drugs for ophthalmic diseases. The product pipeline includes NFS-01 for Leber hereditary optic neuropathy, NFS-04 for glaucoma, NFS-05 for Dominant hereditary optic atrophy, and NFS-10 for vascular retinopathy.
- Aug 2023Series C—
- Apr 2022Series C—
- Nov 2021Series C$63M
- Feb 2021Series B$62M
#3
Series C · Wuhan, Hubei · founded 2010$158.1Mraised▾
Developer of oncolytic virus-based drugs. The company focuses on the research and development of an oncolytic virus (oHSV2) technology platform, and its first product, BS001 (OH2) injection, a multi-indication single drug, and combination drug to treat various solid tumors.
- Apr 2022Series C$47.1M
- Sep 2021Series C—
- Feb 2021Series C$94.9M
- Aug 2018Series B$16.1M
#4
Public · Wuhan, Hubei · founded 2010 · 129 employees$29.8Mraised▾
Wuhan YZY Biopharma is developing humanized monoclonal and bispecific antibodies for oncology applications. The company claims to have six products in the pipeline. The company makes "Y-Body", humanized monoclonal therapeutic antibodies made from a human B cell bank and bi-specific antibodies by antibody engineering technology.
- Jul 2022Series C$29.8M
- Jan 2021Series B—
- Dec 2020Series B—
- May 2016Series A—
#5
Series C · Wuhan, Hubei · founded 2009 · 544 employees$115Mraised▾
Anhan Medical has developed Navicam, a capsule endoscopic robotic system for the early detection of gastrointestinal disease. It is used with the Cruise Capsule Endoscopic Control System and a positioning capsule endoscope system. The system is based on magnetic field precise control and photoelectric imaging technology to achieve control and positioning.
- Oct 2018Series C$100M
- Aug 2017Series B$15M
#6
Series A · Wuhan, Hubei · founded 2015 · 350 employees$15.5Mraised▾
Developer of metabolome products by using metabolome technology for multiple therapeutic areas. The company's products include non-targeted metabolome, short-chain fatty acids, targeted metabolome, plant hormones, oxidized lipids, cell energy metabolism detection, non-targeted, flavonoid metabolome, and others for the fields of life science research and medical health. It also offers plant-based metabolomes such as flavonoid metabolome, terpenoid metabolome, alkaloid metabolome, plant hormone testing, and more that helps in treating multiple metabolic diseases.
- Sep 2021Series A$15.5M
#7
Seed · Wuhan, Hubei · founded 2012$3.9Mraised▾
Developer of nanopore sequencing and bioinformatics analysis technologies. The company is focusing on nanopore sequencing technology in the field of medical clinical pathogenic microorganisms and scientific research products. Its products cover animal and plant genomes, microbial metagenomics, and direct RNA sequencing. Among them, the direct RNA sequencing product created a world record of 18.36G data output on a single chip.
- Dec 2021Seed$3.9M
#8
Series B · Wuhan, Hubei · founded 2013 · 150 employees$7.5Mraised▾
Provider of genomic sequencing services. The company offers third-generation sequencing technology services, 3D genomics technology services, cancer genome medicine services, bioinformatics software development, bioinformatics services, genomic database, and other services.
- Nov 2017Series B$7.5M
#9
Seed · Wuhan, Hubei · founded 2013$2.2Mraised▾
Wuhan Tonggan Medical Technology develops artificial liver and standard human hepatocytes in medium-scale batch production. The HepAssis2 bioartificial liver system is an artificial liver machine developed by the company for improving the working of the liver.
- Sep 2018Seed$2.2M
#10
Seed · Wuhan, Hubei · founded 2015 · 8 employees$767.4Kraised▾
Convergence Technology develops microscopic imaging systems, weak fluorescence detection, and biomedical experimental equipment. The optical genetic solutions include a mouse holder, fiber optics rotary joint, fiber optical splitter, micro microscope, and head connector kit (fiber patch cable, fiber cannula, and ceramic sleeve).
- Dec 2018Seed$767.4K
#11
Series A · Wuhan, Hubei · founded 2019—raised▾
ZYMO RESEARCH is a leading company in the field of biomedical products and services, specializing in Epigenetics, Next-Gen Sequencing, and Microbiome research and diagnostics. Their products enable scientists in academia and the industry to conduct cutting-edge research in these areas.
- Apr 2024Series A—
#12
Series A · Wuhan, Hubei · founded 2019—raised▾
Developer of transdermal drug delivery technology for ophthalmology. It offers a soluble microneedle technology-based microcrystalline eye patch for medical and aesthetic treatment.
- Aug 2022Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Wuhan is moving
A read on the academic research around Biotechnology in Wuhan — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 119 papers.
- Wuhan University52
- Wuhan Polytechnic University16
- Renmin Hospital of Wuhan University15
- Wuhan Union Hospital10
- Wuhan Institute of Virology10
- Mutant1→3
- Mutation1→3
- Cancer cell1→3
- Downregulation and upregulation8
- Cell5
- Cell growth5
- Fermentation5
- Gene4
- Metabolomics2
- Agriculture2
- Microplastics1
- Crop1
- Nutrient1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.